Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resiniferatoxin - Grunenthal

Next Previous
Drug Profile

Resiniferatoxin - Grunenthal

Alternative Names: Lopain; MTX-071; RTX - Grunenthal; RTX-GRT7039

Latest Information Update: 11 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mestex AG
  • Developer Grunenthal
  • Class Acetates; Analgesics; Anti-inflammatories; Azulenes; Non-opioid analgesics; Phenols; Phenyl ethers; Small molecules
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Musculoskeletal pain

Most Recent Events

  • 15 May 2025 Grünenthal completed a phase-III trial in Musculoskeletal pain in USA, Bulgaria, Japan, Poland, Romania, South Africa, and United Kingdom (Intra-articular) (NCT05377489) (EudraCT2021-005046-15)
  • 18 Nov 2024 Grünenthal completes a phase III trials in Musculoskeletal pain in Canada, Czechia, France, Germany, Italy, Japan, Mexico, Netherlands, Poland (Intra-articular, Injection) (EudraCT2021-005029-26) (NCT05248386)
  • 14 Nov 2024 Pharmacokinetics and adverse events data in Musculoskeletal pain presented at the ACR Convergence 2024 (ACR-2024) .

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top